Unexpected Therapeutic Response to Spironolactone: A Prospective Debate on Aldosterone and Potassium Ion in Hypertension
Letter to Editor:
A recent editorial from Goodfriend 1 and the article by Chapman et al, 2 published in Hypertension, addressed the noteworthy pharmacological effects of low doses of spironolactone in patients who failed to respond to 3 antihypertensive drugs. Although the mechanisms responsible for the blood pressurelowering effects of spironolactone are still unclear, the simple fact that a 1-mmol/L increase in serum K was associated with greater systolic blood pressure reduction implies that a reassessment of the role of aldosterone and K ions in essential hypertension is warranted. In this context, 3 major points deserve consideration.
First, the equivocal assumption that serum K accurately reflects body K or cell K function, despite the clinical and experimental evidence, is questionable. In the article by Chapman, 2 serum K was measured at 6-month intervals, and despite treatment with drugs affecting cell K uptake and renal K handling, there was no assessment of intracellular K in these subjects. Second, considering that the renin-angiotensin-aldosterone axis plays a critical role in cell K/Na homeostasis, why was an accurate evaluation of cell Na/K handling and renal Na/K excretion not considered in these patients at the time of spironolactone treatment? This is a critical point considering the current view on hyperkalemia-related morbidity during aldosterone blockade. 3 Third, if such low doses of spironolactone improve the management of hypertension, the use of spironolactone should be carefully reevaluated on the bases of Na intake, body K homeostasis, and used doses. For instance, an increased aldosterone level in a "no-salt" culture, such as Yanomamo, represents a physiological adjustment, 4 very different from the mild-to-high levels of aldosterone in hypertensive subjects with a much higher Na intake. This hormonal adjustment may explain why a low dose of aldosterone blockade might be physiologically helpful in hypertensive subjects, whereas large doses may impair both Na/K homeostasis and BP response.
Our findings of nonsodium-dependant low red-cell K transport in essential hypertensive subjects and in half of the normotensive offspring strongly suggest a defective mechanism (genetic?) in cell K transport, 5 in which an increased plasma aldosterone could be a nonclassical feedback for such cell K depletion, as recorded in normotensive offspring with lower red blood cell K content. Furthermore, studies documenting that aldosterone plays a physiological role in body K homeostasis and cell K distribution 6 might be linked to the protective effects of K in hypertension and organ-target disease as described by Tobian et al. 7 These foregoing considerations, thus, may apply to broader aspects in the evaluation and management of essential hypertension, in which a different approach is necessary for the understanding of body K physiology and disorders that occur in hypertensive subjects or that may follow the administration of antihypertensive drugs. 8 In brief, aldosterone and cell K physiology in essential hypertension remain fascinating topics as they were decades ago, and this editorial and research article certainly confirmed it.
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